Which Study When? lodinated Contrast-enhanced CT Versus Gadolinium-enhanced MR Imaging 1

Radiology

Volumn 249, Issue 1, 2008, Pages 9-15

  Halvorsen, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; GADOLINIUM; GADOLINIUM PENTETATE; IODINATED CONTRAST MEDIUM; IONIC CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM; STEROID; DIAGNOSTIC AGENT; IODINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HYPOTHYROIDISM; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EXTRAVASATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; LARYNX EDEMA; LUNG COLLAPSE; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; URTICARIA; CHEMICALLY INDUCED DISORDER; FEMALE; FETOMATERNAL TRANSFUSION; FIBROSIS; HYPERSENSITIVITY; KIDNEY DISEASE; NOTE;

ANAPHYLAXIS; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; HYPERSENSITIVITY; IODINE; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; MATERNAL-FETAL EXCHANGE; PREGNANCY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 53749100051     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2491080593     Document Type: Article

References (54)

1. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108. [Published correction appears in Nephrol Dial Transplant 2006;21:1745.]
2. Investigation of the safety of MRI contrast medium Omniscan, May 29, 2006. Danish Medicines Agency Website. http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=8931. Accessed November 12, 2007.
3. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. AJR Am J Roentgenol 1998;171:933-939.
4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. JAMA 1996;275:1489-1494.
5. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-374.
6. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983;141:1027-1033.
7. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:1673-1689.
8. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003;181: 1463-1471.
9. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):5K- 13K.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1): S1-S266.
11. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989;36:730-740.
12. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-937.
13. Bassignani MJ, Choudhri AF, Duong PT, Post A, Harrison JH Jr. Comparison between estimated glomerular filtration rate and serum creatinine as a screening tool prior to administration of iodinated contrast material for computed tomography [abstr]. In: Radiological Society of North America Scientific Assembly and Annual Meeting Program. Oak Brook, Ill: Radiological Society of North America, 2007;627.
14. Katzberg RW, Barrett BJ. Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology 2007;243:622- 628.
15. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
16. Lundqvist S, Holmberg G, Jakobsson G, et al. Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function. Acta Radiol 1998;39:362-367.
17. Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation in 1,000 cases. J Am Coll Cardiol 1998;32:1861-1865.
18. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006;239:392-397.
19. Cramer BC, Parfrey PS, Hutchinson TA, et al. Renal function following infusion of radiologic contrast material: a prospective controlled study. Arch Intern Med 1985;145:87-89.
20. Heller CA, Knapp J, Halliday J, O'Connell D, Heller RF. Failure to demonstrate contrast nephrotoxicity. Med J Aust 1991;155:329-332.
21. Erley CM. Does hydration prevent radio contrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:1064-1066.
22. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765-2779.
23. Ergün I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006;21:697-700.
24. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992;27:153-156.
25. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007;188:1447- 1474.
26. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
27. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157.
28. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and non-ionic contrast media. Radiology 1990;175:621- 628.
29. Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001;11:1267-1275.
30. Matthews S. Imaging pulmonary embolism in pregnancy: what is the most appropriate imaging protocol? Br J Radiol 2006;79:441-444.
31. Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: an update. Curr Probl Diagn Radiol 2006;35:164-169.
32. Morcos SK, Thomsen HS, Webb JAW, et al. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol 2001;11:1720-1728.
33. Cohan RH, Ellis JH, Dunnick NR. Use of low-osmolar agents and premedication to reduce the frequency of adverse reactions to radiographic contrast media: a survey of the Society of Uroradiology. Radiology 1995;194:357-364.
34. Wysowski DK, Nourjah P. Deaths attributed to contrast media on U.S. death certificates. AJR Am J Roentgenol 2006;186:613-615.
35. American College of Radiology. Adverse reactions to gadolinium-based contrast agents. In: Manual on contrast media, version 5.0. Reston, Va: American College of Radiology, 41-43.
36. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533-1538.
37. Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656-664.
38. American College of Radiology. Administration of contrast medium to pregnant or potentially pregnant patients. In: Manual on contrast media, version 5.0. Reston, Va: American College of Radiology, 2004;44-45.
39. Moon AJ, Katzberg RW, Sherman MP. Transplacental passage of iohexol. J Pediatr 2000;136:548-549.
40. Panigel M, Wolf G, Zeleznick A. Magnetic resonance imaging of the placenta in rhesus monkeys, Macaca mulatta. J Med Primatol 1988;17:3-18.
41. Nelson JA, Livingston JC, Moon RG. Mutagenic evaluation of radiographic contrast media. Invest Radiol 1982;17:183-185.
42. Morisetti A, Tirone P, Luzzani F, de Haen C. Toxicological safety assessment of iomeprol, a new X-ray contrast agent. Eur J Radiol 1994;18(suppl1):S21-S31.
43. Ralston WH, Robbins MS, James P. Reproductive, developmental, and genetic toxicity of ioversol. Invest Radiol 1989;24(suppl 1):S16-S22.
44. Rodesch F, Camus M, Ermans AM, et al. Adverse effects of amniofetography on fetal thyroid function. Am J Obstet Gynecol 1976;126:723-726.
45. Bona G, Zaffaroni M, Defilippi C, et al. Effects of iopamidol on neonatal thyroid function. Eur J Radiol 1992;14:22-25.
46. Webb JA, Thomsen HS, Morcos SK; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005;15:1234-1240.
47. Rofsky NM, Pizzarello DJ, Weinreb JC, Ambrosino MM, Rosenberg C. Effect on fetal mouse development of exposure to imaging and gadopentetate dimeglumine. J Magn Reson Imaging 1994;4:805- 807.
48. Soltys RA. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992;27(suppl 1):S7-S11.
49. Wible JH Jr, Galen KP, Wojdyla JK. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs. Invest Radiol 2001;36:292-298.
50. Okazaki O, Murayama N, Masubuchi N, Nomura H, Hakusui H. Placental transfer and milk secretion of gadodiamide injection in rats. Arzneimittelforschung 1996;46:83-86.
51. Barkhof F, Heijboer RJ, Algra PR. Inadvertent i.v. administration of gadopentetate dimeglumine during early pregnancy. AJR Am J Roentgenol 1992;158:1171.
52. Shoenut JP, Semelka RC, Silverman R, Yaffe CS, Micflikier AB. MRI in the diagnosis of Crohn's disease in two pregnant women. J Clin Gastroenterol 1993;17:244-247.
53. Garcia-Bournissen F, Shrim A, Koren G. Safety of gadolinium during pregnancy. Can Fam Physician 2006;52:309-310.
54. Coakley F, Gould R. Introduction to risks from MRI during pregnancy. http://www.radiology.ucsf.edu/instruction/abdominal/ab-handbook/ 05-CT-MRI-preg.html. Accessed November 10, 2007.